29 completed, 9 unknown, 5 recruiting, 3 terminated. 18 Not applicable, 13 Phase 2, 8 Phase 1, 5 Early Phase 1, 3 Phase 3.
Follow Intranasal Placebo: new trials by email Literature Review of Intranasal Placebo trials Research Report on Intranasal Placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exercise and Intranasal Insulin in Type 2 Diabetes Intranasal Insulin, Intranasal Placebo, High Intensity Exercise - Type 2 Diabetes, Insulin Sensitivity/Resistance | Phase 2 / Phase 3 | Recruiting | Rutgers, The State University of New Jersey | 60 | 2026-08-03 | 2026-06-30 |
| Oxytocin's Effects on Real Time-fMRI Neurofeedback Training of Anterior Insula Activity Intranasal oxytocin, Intranasal placebo - Healthy | Not applicable | Recruiting | University of Electronic Science and Technology of China | 80 | 2026-04-26 | 2026-04-30 |
| A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder Esketamine, Midazolam, Oral Placebo - Depressive Disorder, Major | Phase 3 | Recruiting | Janssen Research & Development, LLC | 258 | 2026-01-08 | 2026-09-25 |
| The Power of Belief: Expectation-driven and Placebo Modulation of Empathic Pain Intranasal Oxytocin (OT) 24 IU, Intranasal placebo administration - Healthy Participants | Not applicable | Recruiting | University of Electronic Science and Technology of China | 120 | 2025-12-01 | 2026-01-26 |
| Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain Intravenous oxytocin, Intravenous placebo, Intranasal oxytocin - Pain, Acute | Phase 2 | Completed | Wake Forest University Health Sciences | 24 | 2025-11-05 | 2026-06-30 |
| The Effects of Oxytocin and Vasopressin on Delta-beta Cross-frequency Coupling Intranasal Oxytocin (IN-OXT), Intranasal Vasopressin (AVP), Intranasal Placebo - Healthy | Not applicable | Completed | University of Electronic Science and Technology of China | 120 | 2024-10-02 | 2025-10-03 |
| Oxytocin Plus Self-compassion Training in Borderline Personality Disorder Intranasal Oxytocin (IN-OXT), Intranasal Placebo, Self-Compassion Training (SCT) - Self-compassion Training (SCT) Plus Intranasal Oxytocin, Self-compassion Training (SCT) Plus Intranasal Placebo | Phase 2 | Recruiting | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 80 | 2024-01-10 | 2026-04-27 |
| Oxytocin's Effect on the Advantageous- and Disadvantageous-inequity Intranasal oxytocin, Intranasal placebo - Healthy | Not applicable | Completed | University of Electronic Science and Technology of China | 80 | 2024-01-07 | 2024-08-14 |
| Effects of Oxytocin on the Functional Architecture of the Brain Before and After Prolonged Naturalistic Fear Induction intranasal Oxytocin(24IU), intranasal Placebo - Healthy | Not applicable | Completed | University of Electronic Science and Technology of China | 69 | 2023-05-29 | 2025-04-04 |
| Effects of Intranasal Oxytocin on Fear Processing in Naturalistic Contexts intranasal Oxytocin(24IU), intranasal Placebo - Healthy | Not applicable | Completed | University of Electronic Science and Technology of China | 69 | 2023-05-23 | 2025-04-04 |
| Common and Differentiated Representations Between Social Exclusion and Social Separation Intranasal Oxytocin, Intranasal Arginine Vasopressin, Intranasal placebo - Healthy | Not applicable | Unknown | University of Electronic Science and Technology of China | 120 | 2023-04-20 | 2023-06-28 |
| The Effects of Intranasal and Oral Administration of Oxytocin on Responses to Emotional Scenes Oral Oxytocin, Intranasal Oxytocin, Oral placebo - Healthy | Not applicable | Unknown | University of Electronic Science and Technology of China | 160 | 2022-09-20 | 2022-09-08 |
| Does Oxytocin Alter Tolerance to or Motivation for Alcohol Intranasal oxytocin, Intranasal placebo - Alcohol Use Disorder | Phase 2 | Terminated | Indiana University | 6 | 2022-01-16 | 2025-03-04 |
| Stimulation Test With Intranasal Glucagon for Corticotroph, Somatotroph and Antidiuretic Axes Intranasal glugagon, Intranasal placebo - Hypopituitarism | Phase 4 | Completed | A.O.U. Città della Salute e della Scienza | 10 | 2021-10-01 | 2022-01-25 |
| Is Brain Insulin Resistance a Feature of the Biology of Depression in Adolescents Humalog, Saline nasal spray - Major Depressive Disorder, Depression | Not applicable | Completed | Centre for Addiction and Mental Health | 24 | 2021-09-01 | 2026-03-31 |
| Effects of Oxytocin on Reinforcement Learning and Interoception Intranasal oxytocin, intranasal placebo - Healthy | Not applicable | Completed | University of Electronic Science and Technology of China | 80 | 2021-04-15 | 2024-01-19 |
| AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery Intranasal Drug, Oral Tablet, Intranasal Placebo - Vestibular Vertigo | Phase 2 | Completed | Auris Medical AG | 124 | 2019-07-18 | 2023-09-14 |
| Effects of Oxytocin on Reinforcement Learning intranasal oxytocin, intranasal placebo - Learning Disabilities | Not applicable | Unknown | University of Electronic Science and Technology of China | 40 | 2018-12-04 | 2019-02-19 |
| Intranasal Oxytocin as Enhancer of Psychotherapy Outcomes in Severe Mental Illness Intranasal Oxytocin, Intranasal Placebo - Severe Mental Illness | Phase 2 | Unknown | Shalvata Mental Health Center | 120 | 2018-06-01 | 2024-06-28 |
| Effect of Intranasal Insulin on Cognitive Processes and Appetite Intranasal Insulin, Intranasal Placebo - Obesity | Not applicable | Completed | University of Birmingham | 64 | 2018-04-23 | 2019-05-02 |
Showing 20 of 47. Sign in to see all of them.
Diabetes Insipidus (6) · Insulin Resistance (5) · Pain, Postoperative (5) · Agnosia (3) · Depressive Disorder, Major (3) · Diabetes Mellitus, Type 2 (3) · Borderline Personality Disorder (2) · Bunion (2) · Depression (2) · Diabetes Mellitus (2) · Pain (2) · Substance-Related Disorders (2) · Acute Pain (1) · Alcohol Drinking (1) · Alcoholism (1)
University of Electronic Science and Technology of China (14) · University of California, Los Angeles (5) · Janssen Research & Development, LLC (4) · University Health Network, Toronto (3) · Baudax Bio (2) · Javelin Pharmaceuticals (2) · A.O.U. Città della Salute e della Scienza (1) · Auris Medical AG (1) · Baylor College of Medicine (1) · Centre for Addiction and Mental Health (1) · David Mankuta (1) · Egalet Ltd (1) · Emory University (1) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) · Icahn School of Medicine at Mount Sinai (1)
United States (19) · China (15) · Canada (3) · Italy (3) · Spain (3) · Brazil (2) · France (2) · Hungary (2) · Israel (2) · Belgium (1) · Bulgaria (1) · Germany (1) · New Zealand (1) · Poland (1) · Romania (1)
Matthew D Lieberman, PhD (3) · Benjamin Becker, Dr. (2) · Neil Singla, MD (2) · Yao Shuxia, Dr (2) · Benjamin Becker (1) · Christopher Stauffer, MD (1) · David Mankuta, MD (1) · Douglas G Stoker, DPM (1) · Harold Koenigsberg, MD (1) · James C Eisenach, MD (1) · James K Rilling, Ph.D. (1) · Juan Kou, MSc (1) · Keith Kendrick, Dr. (1) · Keith Kendrick, PhD (1)
PMID 37310308, PMID 25462898, PMID 27053769, PMID 28730676, PMID 31128568, PMID 31174846, PMID 32848571, PMID 33128208, PMID 33343285, PMID 34397100, PMID 36905736, PMID 40058488
1IK2CX001495-01 (1), 2014 (1), 2016 (1), 2018 (1), R01DK147509 (1), R01MH084068 (1), UL1TR000067 (1)